Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a9e6421e9257148abad101e1ce6c162 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 |
filingDate |
2006-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2012-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_192b203563abe67a9ed84666994268df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f22544ec1cfd67684f9ee1f7aadcb870 |
publicationDate |
2012-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2006301579-B2 |
titleOfInvention |
EGLN2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases |
abstract |
The invention relates to human EGLN2-variants having a serine or a leucine in position 58 of the amino acid sequence and to the use thereof in preventing or treating thromboembolic disorders or coronary heart diseases, in particular, cerebral apoplexy, prolonged reversible ischaemic neurological deficit (PRIND), transient ischaemic attack (TIA), myocardial infarct and/or premature myocardial infarct. |
priorityDate |
2005-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |